Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD) that can lead to liver cirrhosis and related complications, including cancer. MASLD affects approximately 25% of the general global population and is increasing in prevalence with rising rates of type 2 diabetes, metabolic syndrome, and obesity.1
Multiple compounds are in development for the treatment of MASH/MASLD, but there are barriers to drug development including the lack of a gold standard measure of MASLD activity and validated outcomes that are responsive to change following effective therapeutic intervention.
Cutting-edge central imaging histopathology solutions and processes to block, cut, stain, and digitize liver biopsies for central review.
A proprietary image management software solution, Lucidity™ ensures secure and efficient processing of your digitized slides.
Highly trained central GI pathologist readers with disease-specific expertise to reduce histopathologic outcome variability.
Collaborations with global liver disease experts to refine histopathologic outcome measures, standardize scoring conventions, and improve assessment reliability.
Global network of 5000+ sites in>60 countries – and growing in ASIA-PAC and South America.
1. van Son, K C et al. “Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.” Medicine vol. 103,1 (2024): e34934. doi:10.1097/MD.0000000000034934
